{"success":true,"data":{"pressRelease":{"id":"77778","rtpr_id":"nPn8s0QTwa","ticker":"NOVOB","exchange":"Nasdaq Copenhagen","all_tickers":["NOVOB"],"title":"Wegovy® is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge","author":"PR Newswire","published_at":"2026-07-01T11:00:04.764Z","article_body":"Wegovy® is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge\n\nPR Newswire\n\nPLAINSBORO, N.J., July 1, 2026\n\n * Starting today, eligible Medicare patients living with obesity can access\nWegovy(®) (semaglutide) injection and pill for a $50 monthly copay\n * Wegovy(®) offers adults living with obesity significant weight loss, along\nwith diet and exercise, and is FDA-approved to lower the risk of major\ncardiovascular events – including death, heart attack, or stroke in adults\nwith obesity and heart disease – a claim only Wegovy(®) can make\n * Since launching in January 2026, Wegovy(®) pill has reached 3 million\nprescriptions(* )– Medicare GLP-1 Bridge participation now expands patient\naccess to authentic, FDA-approved Wegovy(®), including the Wegovy(®) pill\nPLAINSBORO, N.J., July 1, 2026 /PRNewswire/ -- Starting today FDA-approved\nWegovy(®) (semaglutide) is available through the Medicare GLP-1 Bridge, a new\naccess pathway for millions of older adults living with obesity. Obesity is a\nserious, common chronic disease among older Americans and Wegovy(®) is the\nonly weight management medicine proven to reduce the risk of major heart\nevents, heart attack, stroke, or cardiovascular death in people with obesity\nand known heart disease. This is an important distinction for adults age 65\nand older who have a high burden of both obesity and cardiovascular disease.\nEligible Medicare beneficiaries can now access Wegovy(®) injection and pill\nfor a $50 monthly copay(†) through the program, which runs through the end\nof 2027.\n\n(https://mma.prnewswire.com/media/3002632/Wegovy_Pens_Combined.html)\n\n\"For many older Americans living with obesity, this is a moment they and their\nfamilies have been waiting for. The Medicare GLP-1 Bridge program offers a\nnew, affordable path to an FDA-approved treatment that was previously not\ncovered,\" said Jamey Millar, Executive Vice President, US Operations of Novo\nNordisk. \"The fact that Wegovy(®) is the only weight loss medicine proven to\nreduce the risk of heart attack, stroke, or cardiovascular death in patients\nwith known heart disease and obesity makes this access moment particularly\nimportant for eligible Medicare beneficiaries. We are committed to helping\npatients, caregivers, and healthcare professionals navigate this program with\nconfidence.\"\n\nThe Medicare GLP-1 Bridge is available nationwide across all states and\nterritories. To access Wegovy(®) through the program, eligible Medicare\nbeneficiaries can take these steps:\n\n * Talk to your doctor. Ask whether Wegovy(®) is right for you and if you may\nqualify for the Medicare GLP-1 Bridge.\n * Your doctor will send a prescription to your pharmacy and submit the\nnecessary prior authorization to CMS when requested by the pharmacy on your\nbehalf.\n * Pick up your medication at your pharmacy and pay $50 for a one-month\nsupply.(†) Once approved, refills do not require a new prior authorization\nas long as you stay on the same GLP-1 medication.\nThe Medicare GLP-1 Bridge provides eligible patients access to Wegovy(®)\nspecifically for weight management. It is important to note that Wegovy(®)\nwill remain available for eligible Medicare beneficiaries for other\nFDA-approved indications through their normal Part D benefits, including to\nreduce the risk of major adverse cardiovascular events in adults with\nestablished CV disease with either obesity or overweight.\n\n\"The Medicare GLP-1 Bridge program is a significant step forward for people\nliving with obesity who have long faced barriers to access under Medicare,\"\nsaid Joe Nadglowski, President and CEO of the Obesity Action Coalition (OAC).\n\"At the OAC, we've long advocated for policies that recognize obesity as a\nchronic disease and provide patients access to FDA-approved treatment options.\nThis program offers new hope for Medicare beneficiaries who may finally be\nable to access obesity medications at an affordable cost. While the Bridge is\nan important milestone, it should also be a catalyst for creating a permanent\npathway to comprehensive obesity care within Medicare and across private\ninsurance as well.\"\n\nNovo Nordisk is actively working with CMS, healthcare professionals,\npharmacists, and patient advocacy organizations to support implementation and\nhelp ensure patients can access the medicines they need. Expanding affordable\naccess to medicines is a priority for Novo Nordisk, and the Medicare GLP-1\nBridge builds on a sustained effort to ensure patients can access authentic,\nFDA-approved Wegovy(®). As a leader in the GLP-1 medicine category, Novo\nNordisk has increased access through initiatives like NovoCare(®) Pharmacy,\ntelehealth collaborations, and retail partnerships to help patients get\nauthentic, FDA-approved medicines without having to turn to unsafe\nalternatives. For more information about the Medicare GLP-1 Bridge, patients\nare encouraged to speak with their healthcare professional. If you need\nsupport or have questions, connect with the NovoCare(®) Obesity and Medicare\nGLP-1 Bridge Support Team at 1-888-809-3942, available 8:00 AM – 8:00 PM ET.\nYou can also find up-to-date information anytime by visiting:\nhttps://www.wegovy.com/medicare.html\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=656037701&u=https%3A%2F%2Fwww.wegovy.com%2Fmedicare.html&a=https%3A%2F%2Fwww.wegovy.com%2Fmedicare.html)\n\n(* )The source data for the over 3 million prescriptions for all strengths of\nWegovy(®) pill includes Novo Nordisk Inc. partner-reported paid claims only\nfrom January 5, 2026 through June 2, 2026.\n(†)Terms apply. For eligible Medicare patients prescribed Wegovy(®) for a\ncovered FDA-approved indication. Eligibility criteria will be determined by\nCMS. This information is not a guarantee of coverage. Month defined as 1 box\nof 4 pens of Wegovy(®) and 1 bottle of 30 tablets of Wegovy(®.)\n\nAbout obesity\nObesity is a serious, chronic, progressive, and complex disease that requires\nlong-term management.(1-3) One key misunderstanding is that this is a disease\nof just lack of willpower, when in fact there is underlying biology that may\nimpede people living with obesity from losing weight and keeping it\noff.(1,3) Obesity is influenced by a variety of factors, including genetics,\nsocial determinants of health, and the environment.(4,5)\n\nAbout Novo Nordisk\nNovo Nordisk is a leading global healthcare company that's been making\ninnovative medicines to help people with diabetes lead longer, healthier lives\nfor more than 100 years. This heritage has given us experience and\ncapabilities that also enable us to drive change to help people defeat other\nserious chronic diseases such as obesity, rare blood, and endocrine disorders.\nWe remain steadfast in our conviction that the formula for lasting success is\nto stay focused, think long-term, and do business in a financially, socially,\nand environmentally responsible way. With a US presence spanning 40 years,\nNovo Nordisk US is headquartered in New Jersey and employs approximately\n10,000 people throughout the country across more than 10 manufacturing,\nR&D and corporate locations in seven states plus Washington DC. For more\ninformation, visit novonordisk-us.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=226148825&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4365868-1%26h%3D3558636689%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4349237-1%2526h%253D2350167128%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4248685-1%252526h%25253D1648513612%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D4243585-1%25252526h%2525253D3380893495%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D4109213-1%2525252526h%252525253D808952762%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fwww.novonordisk-us.com%25252525252F%2525252526a%252525253Dnovonordisk-us.com%25252526a%2525253Dnovonordisk-us.com%252526a%25253Dnovonordiskus.com%2526a%253Dnovonordisk-us.com%26a%3Dnovonordisk-us.com&a=novonordisk-us.com)\n, Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=3320689644&u=https%3A%2F%2Fwww.facebook.com%2FNovoNordiskUS%2F&a=Facebook)\n, Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=804552947&u=https%3A%2F%2Fwww.instagram.com%2Faccounts%2Flogin%2F%3Fnext%3Dhttps%253A%252F%252Fwww.instagram.com%252Fnovonordiskus%252F%26is_from_rle&a=Instagram)\n, and X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=1739412952&u=https%3A%2F%2Fx.com%2Fnovonordiskus&a=X)\n.\n\nWhat is Wegovy(®)? Wegovy(®) (semaglutide) injection is a prescription\nmedicine used with a reduced-calorie diet and increased physical activity to:\n\n * reduce the risk of major cardiovascular events such as death, heart attack, or\nstroke in adults with known heart disease and with either obesity or\noverweight.\n * help adults and children aged 12 years and older with obesity, or some adults\nwith excess weight (overweight) who also have weight-related medical problems\nto lose weight and keep the weight off.\nWegovy(®) (semaglutide) tablets are a prescription medicine used with a\nreduced-calorie diet and increased physical activity to:\n\n * reduce the risk of major cardiovascular events such as death, heart attack, or\nstroke in adults with known heart disease and with either obesity or\noverweight.\n * help adults with obesity, or some adults with excess weight (overweight) who\nalso have weight-related medical problems to lose weight and keep the weight\noff.\nWegovy(®) contains semaglutide and should not be used with other\nsemaglutide-containing products or other GLP-1 receptor agonist medicines.\n\nIt is not known if Wegovy(®) injection is safe and effective:\n\n * to reduce the risk of major cardiovascular events (death, heart attack, or\nstroke) in people under 18 years\n * to help children under 12 years of age lose weight and keep the weight off\nIt is not known if Wegovy(®) tablets are safe and effective for use in people\nunder 18 years of age.\n\nImportant Safety Information\n\nWhat is the most important information I should know about\nWegovy(®)? Wegovy(®) may cause serious side effects, including:\n\n * Possible thyroid tumors, including cancer. Tell your healthcare provider if\nyou get a lump or swelling in your neck, hoarseness, trouble swallowing, or\nshortness of breath. These may be symptoms of thyroid cancer. In studies with\nrodents, Wegovy(®) and other medicines that work like Wegovy(®) caused\nthyroid tumors, including thyroid cancer. It is not known if Wegovy(®) will\ncause thyroid tumors or a type of thyroid cancer called medullary thyroid\ncarcinoma (MTC) in people\n * Do not use Wegovy(®) if you or any of your family have ever had a type of\nthyroid cancer called medullary thyroid carcinoma (MTC) or if you have an\nendocrine system condition called Multiple Endocrine Neoplasia syndrome type 2\n(MEN 2)\nDo not use Wegovy(®) if:\n\n * you or any of your family have ever had a type of thyroid cancer called\nmedullary thyroid carcinoma (MTC) or if you have an endocrine system condition\ncalled Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n * you have had a serious allergic reaction to semaglutide or any of the\ningredients in Wegovy(®) injection or Wegovy(®) tablets. See symptoms of\nserious allergic reaction in \"What are the possible side effects of\nWegovy(®)?\"\nWegovy(®) FlexTouch(®) pen: Do not share your Wegovy(®) FlexTouch(®) pen\nwith other people, even if the needle has been changed. You may give other\npeople a serious infection or get a serious infection from them.\n\nBefore using Wegovy(®,) tell your healthcare provider if you have any other\nmedical conditions, including if you:\n\n * have or have had problems with your pancreas or kidneys\n * have type 2 diabetes and a history of diabetic retinopathy\n * are scheduled to have surgery or other procedures that use anesthesia or deep\nsleepiness (deep sedation)\n * are pregnant or plan to become pregnant. Wegovy(®) may harm your unborn baby.\nYou should stop using Wegovy(®) 2 months before you plan to become pregnant\n * are breastfeeding or plan to breastfeed. Breastfeeding is not recommended\nduring treatment with Wegovy(®) tablets. It is not known if Wegovy(®) when\nreceived through an injection passes into your breast milk\nTell your healthcare provider about all the medicines you take, including\nprescription and over-the-counter medicines, vitamins, and herbal supplements.\nWegovy(®) may affect the way some medicines work and some medicines may\naffect the way Wegovy(®) works. Tell your healthcare provider if you are\ntaking other medicines to treat diabetes, including sulfonylureas or insulin.\nWegovy(®) slows stomach emptying and can affect medicines that need to pass\nthrough the stomach quickly.\n\nWhat are the possible side effects of Wegovy(®)? Wegovy(®) may cause serious\nside effects, including:\n\n * inflammation of your pancreas (pancreatitis). Stop using Wegovy(®) and call\nyour healthcare provider right away if you have severe pain in your stomach\narea (abdomen) that will not go away, with or without nausea or vomiting.\nSometimes you may feel the pain from your abdomen to your back\n * gallbladder problems. Wegovy(®) may cause gallbladder problems, including\ngallstones. Some gallstones may need surgery. Call your healthcare provider if\nyou have symptoms, such as pain in your upper stomach (abdomen), fever,\nyellowing of the skin or eyes (jaundice), or clay-colored stools\n * increased risk of low blood sugar (hypoglycemia), especially those who also\ntake medicines for diabetes such as insulin or sulfonylureas. This can be a\nserious side effect. Talk to your healthcare provider about how to recognize\nand treat low blood sugar and check your blood sugar before you start and\nwhile you take Wegovy(®). Signs and symptoms of low blood sugar may include\ndizziness or light-headedness, blurred vision, anxiety, irritability or mood\nchanges, sweating, slurred speech, hunger, confusion or drowsiness, shakiness,\nweakness, headache, fast heartbeat, or feeling jittery\n * dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may\ncause a loss of fluids (dehydration), which may cause kidney problems. It is\nimportant for you to drink fluids to help reduce your chance of dehydration.\nTell your healthcare provider right away if you have nausea, vomiting, or\ndiarrhea that does not go away\n * severe stomach problems. Stomach problems, sometimes severe, have been\nreported in people who use Wegovy(®.) Tell your healthcare provider if you\nhave stomach problems that are severe or will not go away\n * serious allergic reactions. Stop using Wegovy(®) and get medical help right\naway if you have any symptoms of a serious allergic reaction, including\nswelling of your face, lips, tongue, or throat; problems breathing or\nswallowing; severe rash or itching; fainting or feeling dizzy; or very rapid\nheartbeat\n * change in vision in people with type 2 diabetes. Tell your healthcare provider\nif you have changes in vision during treatment with Wegovy(®)\n * increased heart rate. Wegovy(®) can increase your heart rate while you are at\nrest. Tell your healthcare provider if you feel your heart racing or pounding\nin your chest and it lasts for several minutes\n * food or liquid getting into the lungs during surgery or other procedures that\nuse anesthesia or deep sleepiness (deep sedation). Wegovy(®) may increase the\nchance of food getting into your lungs during surgery or other procedures.\nTell all your healthcare providers that you are taking Wegovy(®) before you\nare scheduled to have surgery or other procedures\nThe most common side effects of Wegovy(®) may include: nausea, diarrhea,\nvomiting, constipation, stomach (abdomen) pain, changes in skin sensations,\nheadache, tiredness (fatigue), upset stomach, dizziness, feeling bloated,\nbelching, low blood sugar in people with type 2 diabetes, gas, stomach flu,\nheartburn, and hair loss.\n\nPlease click here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=3558436216&u=https%3A%2F%2Fwww.novo-pi.com%2Fwegovy.pdf&a=here)\n for Prescribing Information including Boxed Warning and Medication\nGuide for Wegovy(®).\n Contacts for further information\n Media:\n Liz Skrbkova (US)                                       Ambre James-Brown (Global)\n +1 609 917 0632                                         +45 3079 9289\n\nUSMediaRelations@novonordisk.com                       Globalmedia@novonordisk.com (mailto:Globalmedia@novonordisk.com)\n (mailto:USMediaRelations@novonordisk.com)\n Investors:\n Frederik Taylor Pitter (US)\n\n+1 609 613 0568\n fptr@novonordisk.com (mailto:fptr@novonordisk.com) \"\n\n Michael Novod (Global)                                  Jacob Martin Wiborg Rode (Global)\n\n+45 3075 6050\n+45 3075 5956\n nvno@novonordisk.com (mailto:nvno@novonordisk.com)      jrde@novonordisk.com (mailto:jrde@novonordisk.com)\n Sina Meyer (Global)                                     Max Ung (Global)\n\n+45 3079 6656\n+45 3077 6414\n azey@novonordisk.com (mailto:azey@novonordisk.com)      mxun@novonordisk.com (mailto:mxun@novonordisk.com)\n Christoffer Sho Togo Tullin (Global)                    Alex Bruce (Global)\n\n+45 3079 1471\n+45 3444 2613\n cftu@novonordisk.com (mailto:cftu@novonordisk.com)      axeu@novonordisk.com (mailto:axeu@novonordisk.com)\n Mads Berner Bruun (Global)\n +45 3075 2936\n mbbz@novonordisk.com (mailto:mbbz@novonordisk.com)\n\nReferences:\n\n 1. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective\nobesity care: results from the national action study. Obesity.\n2018;26(1):61–69.\n 2. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic\nrelapsing progressive disease process. A position statement of the World\nObesity Federation. Obes Rev. 2017;18(7):715–723.\n 3. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical\nendocrinologists and American College of Endocrinology comprehensive clinical\npractice guidelines for medical care of patients with obesity. Endocr Pract.\n2016;22 (Suppl 3):1–203.\n 4. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults\nwith overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI:\n10.1056/NEJMoa2500969.\n 5. Centers for Disease Control and Prevention. Risk Factors for Obesity. Last\naccessed: December 2025. Available at:\nhttps://www.cdc.gov/obesity/risk-factors/risk-factors.html\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=2040965910&u=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Frisk-factors%2Frisk-factors.html&a=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Frisk-factors%2Frisk-factors.html)\n \n\n(https://mma.prnewswire.com/media/3002633/Wegovy_Pill_Combined.html)\n\n(https://mma.prnewswire.com/media/2751477/novo_Logo.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/wegovy-is-now-accessible-to-eligible-medicare-beneficiaries-living-with-obesity-through-medicare-glp-1-bridge-302815200.html\n(https://www.prnewswire.com/news-releases/wegovy-is-now-accessible-to-eligible-medicare-beneficiaries-living-with-obesity-through-medicare-glp-1-bridge-302815200.html)\n\nSOURCE Novo Nordisk\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/3002632/Wegovy_Pens_Combined.jpg\nhttps://mma.prnewswire.com/media/3002633/Wegovy_Pill_Combined.jpg\nhttps://mma.prnewswire.com/media/2751477/novo_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn8s0QTwa","title":"Wegovy® is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge","author":"PR Newswire","ticker":"NOVOB","created":"2026-07-01T11:00:04.764Z","tickers":["NOVOB"],"exchange":"Nasdaq Copenhagen","article_body":"Wegovy® is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge\n\nPR Newswire\n\nPLAINSBORO, N.J., July 1, 2026\n\n * Starting today, eligible Medicare patients living with obesity can access\nWegovy(®) (semaglutide) injection and pill for a $50 monthly copay\n * Wegovy(®) offers adults living with obesity significant weight loss, along\nwith diet and exercise, and is FDA-approved to lower the risk of major\ncardiovascular events – including death, heart attack, or stroke in adults\nwith obesity and heart disease – a claim only Wegovy(®) can make\n * Since launching in January 2026, Wegovy(®) pill has reached 3 million\nprescriptions(* )– Medicare GLP-1 Bridge participation now expands patient\naccess to authentic, FDA-approved Wegovy(®), including the Wegovy(®) pill\nPLAINSBORO, N.J., July 1, 2026 /PRNewswire/ -- Starting today FDA-approved\nWegovy(®) (semaglutide) is available through the Medicare GLP-1 Bridge, a new\naccess pathway for millions of older adults living with obesity. Obesity is a\nserious, common chronic disease among older Americans and Wegovy(®) is the\nonly weight management medicine proven to reduce the risk of major heart\nevents, heart attack, stroke, or cardiovascular death in people with obesity\nand known heart disease. This is an important distinction for adults age 65\nand older who have a high burden of both obesity and cardiovascular disease.\nEligible Medicare beneficiaries can now access Wegovy(®) injection and pill\nfor a $50 monthly copay(†) through the program, which runs through the end\nof 2027.\n\n(https://mma.prnewswire.com/media/3002632/Wegovy_Pens_Combined.html)\n\n\"For many older Americans living with obesity, this is a moment they and their\nfamilies have been waiting for. The Medicare GLP-1 Bridge program offers a\nnew, affordable path to an FDA-approved treatment that was previously not\ncovered,\" said Jamey Millar, Executive Vice President, US Operations of Novo\nNordisk. \"The fact that Wegovy(®) is the only weight loss medicine proven to\nreduce the risk of heart attack, stroke, or cardiovascular death in patients\nwith known heart disease and obesity makes this access moment particularly\nimportant for eligible Medicare beneficiaries. We are committed to helping\npatients, caregivers, and healthcare professionals navigate this program with\nconfidence.\"\n\nThe Medicare GLP-1 Bridge is available nationwide across all states and\nterritories. To access Wegovy(®) through the program, eligible Medicare\nbeneficiaries can take these steps:\n\n * Talk to your doctor. Ask whether Wegovy(®) is right for you and if you may\nqualify for the Medicare GLP-1 Bridge.\n * Your doctor will send a prescription to your pharmacy and submit the\nnecessary prior authorization to CMS when requested by the pharmacy on your\nbehalf.\n * Pick up your medication at your pharmacy and pay $50 for a one-month\nsupply.(†) Once approved, refills do not require a new prior authorization\nas long as you stay on the same GLP-1 medication.\nThe Medicare GLP-1 Bridge provides eligible patients access to Wegovy(®)\nspecifically for weight management. It is important to note that Wegovy(®)\nwill remain available for eligible Medicare beneficiaries for other\nFDA-approved indications through their normal Part D benefits, including to\nreduce the risk of major adverse cardiovascular events in adults with\nestablished CV disease with either obesity or overweight.\n\n\"The Medicare GLP-1 Bridge program is a significant step forward for people\nliving with obesity who have long faced barriers to access under Medicare,\"\nsaid Joe Nadglowski, President and CEO of the Obesity Action Coalition (OAC).\n\"At the OAC, we've long advocated for policies that recognize obesity as a\nchronic disease and provide patients access to FDA-approved treatment options.\nThis program offers new hope for Medicare beneficiaries who may finally be\nable to access obesity medications at an affordable cost. While the Bridge is\nan important milestone, it should also be a catalyst for creating a permanent\npathway to comprehensive obesity care within Medicare and across private\ninsurance as well.\"\n\nNovo Nordisk is actively working with CMS, healthcare professionals,\npharmacists, and patient advocacy organizations to support implementation and\nhelp ensure patients can access the medicines they need. Expanding affordable\naccess to medicines is a priority for Novo Nordisk, and the Medicare GLP-1\nBridge builds on a sustained effort to ensure patients can access authentic,\nFDA-approved Wegovy(®). As a leader in the GLP-1 medicine category, Novo\nNordisk has increased access through initiatives like NovoCare(®) Pharmacy,\ntelehealth collaborations, and retail partnerships to help patients get\nauthentic, FDA-approved medicines without having to turn to unsafe\nalternatives. For more information about the Medicare GLP-1 Bridge, patients\nare encouraged to speak with their healthcare professional. If you need\nsupport or have questions, connect with the NovoCare(®) Obesity and Medicare\nGLP-1 Bridge Support Team at 1-888-809-3942, available 8:00 AM – 8:00 PM ET.\nYou can also find up-to-date information anytime by visiting:\nhttps://www.wegovy.com/medicare.html\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=656037701&u=https%3A%2F%2Fwww.wegovy.com%2Fmedicare.html&a=https%3A%2F%2Fwww.wegovy.com%2Fmedicare.html)\n\n(* )The source data for the over 3 million prescriptions for all strengths of\nWegovy(®) pill includes Novo Nordisk Inc. partner-reported paid claims only\nfrom January 5, 2026 through June 2, 2026.\n(†)Terms apply. For eligible Medicare patients prescribed Wegovy(®) for a\ncovered FDA-approved indication. Eligibility criteria will be determined by\nCMS. This information is not a guarantee of coverage. Month defined as 1 box\nof 4 pens of Wegovy(®) and 1 bottle of 30 tablets of Wegovy(®.)\n\nAbout obesity\nObesity is a serious, chronic, progressive, and complex disease that requires\nlong-term management.(1-3) One key misunderstanding is that this is a disease\nof just lack of willpower, when in fact there is underlying biology that may\nimpede people living with obesity from losing weight and keeping it\noff.(1,3) Obesity is influenced by a variety of factors, including genetics,\nsocial determinants of health, and the environment.(4,5)\n\nAbout Novo Nordisk\nNovo Nordisk is a leading global healthcare company that's been making\ninnovative medicines to help people with diabetes lead longer, healthier lives\nfor more than 100 years. This heritage has given us experience and\ncapabilities that also enable us to drive change to help people defeat other\nserious chronic diseases such as obesity, rare blood, and endocrine disorders.\nWe remain steadfast in our conviction that the formula for lasting success is\nto stay focused, think long-term, and do business in a financially, socially,\nand environmentally responsible way. With a US presence spanning 40 years,\nNovo Nordisk US is headquartered in New Jersey and employs approximately\n10,000 people throughout the country across more than 10 manufacturing,\nR&D and corporate locations in seven states plus Washington DC. For more\ninformation, visit novonordisk-us.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=226148825&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4365868-1%26h%3D3558636689%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4349237-1%2526h%253D2350167128%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4248685-1%252526h%25253D1648513612%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D4243585-1%25252526h%2525253D3380893495%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D4109213-1%2525252526h%252525253D808952762%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fwww.novonordisk-us.com%25252525252F%2525252526a%252525253Dnovonordisk-us.com%25252526a%2525253Dnovonordisk-us.com%252526a%25253Dnovonordiskus.com%2526a%253Dnovonordisk-us.com%26a%3Dnovonordisk-us.com&a=novonordisk-us.com)\n, Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=3320689644&u=https%3A%2F%2Fwww.facebook.com%2FNovoNordiskUS%2F&a=Facebook)\n, Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=804552947&u=https%3A%2F%2Fwww.instagram.com%2Faccounts%2Flogin%2F%3Fnext%3Dhttps%253A%252F%252Fwww.instagram.com%252Fnovonordiskus%252F%26is_from_rle&a=Instagram)\n, and X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=1739412952&u=https%3A%2F%2Fx.com%2Fnovonordiskus&a=X)\n.\n\nWhat is Wegovy(®)? Wegovy(®) (semaglutide) injection is a prescription\nmedicine used with a reduced-calorie diet and increased physical activity to:\n\n * reduce the risk of major cardiovascular events such as death, heart attack, or\nstroke in adults with known heart disease and with either obesity or\noverweight.\n * help adults and children aged 12 years and older with obesity, or some adults\nwith excess weight (overweight) who also have weight-related medical problems\nto lose weight and keep the weight off.\nWegovy(®) (semaglutide) tablets are a prescription medicine used with a\nreduced-calorie diet and increased physical activity to:\n\n * reduce the risk of major cardiovascular events such as death, heart attack, or\nstroke in adults with known heart disease and with either obesity or\noverweight.\n * help adults with obesity, or some adults with excess weight (overweight) who\nalso have weight-related medical problems to lose weight and keep the weight\noff.\nWegovy(®) contains semaglutide and should not be used with other\nsemaglutide-containing products or other GLP-1 receptor agonist medicines.\n\nIt is not known if Wegovy(®) injection is safe and effective:\n\n * to reduce the risk of major cardiovascular events (death, heart attack, or\nstroke) in people under 18 years\n * to help children under 12 years of age lose weight and keep the weight off\nIt is not known if Wegovy(®) tablets are safe and effective for use in people\nunder 18 years of age.\n\nImportant Safety Information\n\nWhat is the most important information I should know about\nWegovy(®)? Wegovy(®) may cause serious side effects, including:\n\n * Possible thyroid tumors, including cancer. Tell your healthcare provider if\nyou get a lump or swelling in your neck, hoarseness, trouble swallowing, or\nshortness of breath. These may be symptoms of thyroid cancer. In studies with\nrodents, Wegovy(®) and other medicines that work like Wegovy(®) caused\nthyroid tumors, including thyroid cancer. It is not known if Wegovy(®) will\ncause thyroid tumors or a type of thyroid cancer called medullary thyroid\ncarcinoma (MTC) in people\n * Do not use Wegovy(®) if you or any of your family have ever had a type of\nthyroid cancer called medullary thyroid carcinoma (MTC) or if you have an\nendocrine system condition called Multiple Endocrine Neoplasia syndrome type 2\n(MEN 2)\nDo not use Wegovy(®) if:\n\n * you or any of your family have ever had a type of thyroid cancer called\nmedullary thyroid carcinoma (MTC) or if you have an endocrine system condition\ncalled Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n * you have had a serious allergic reaction to semaglutide or any of the\ningredients in Wegovy(®) injection or Wegovy(®) tablets. See symptoms of\nserious allergic reaction in \"What are the possible side effects of\nWegovy(®)?\"\nWegovy(®) FlexTouch(®) pen: Do not share your Wegovy(®) FlexTouch(®) pen\nwith other people, even if the needle has been changed. You may give other\npeople a serious infection or get a serious infection from them.\n\nBefore using Wegovy(®,) tell your healthcare provider if you have any other\nmedical conditions, including if you:\n\n * have or have had problems with your pancreas or kidneys\n * have type 2 diabetes and a history of diabetic retinopathy\n * are scheduled to have surgery or other procedures that use anesthesia or deep\nsleepiness (deep sedation)\n * are pregnant or plan to become pregnant. Wegovy(®) may harm your unborn baby.\nYou should stop using Wegovy(®) 2 months before you plan to become pregnant\n * are breastfeeding or plan to breastfeed. Breastfeeding is not recommended\nduring treatment with Wegovy(®) tablets. It is not known if Wegovy(®) when\nreceived through an injection passes into your breast milk\nTell your healthcare provider about all the medicines you take, including\nprescription and over-the-counter medicines, vitamins, and herbal supplements.\nWegovy(®) may affect the way some medicines work and some medicines may\naffect the way Wegovy(®) works. Tell your healthcare provider if you are\ntaking other medicines to treat diabetes, including sulfonylureas or insulin.\nWegovy(®) slows stomach emptying and can affect medicines that need to pass\nthrough the stomach quickly.\n\nWhat are the possible side effects of Wegovy(®)? Wegovy(®) may cause serious\nside effects, including:\n\n * inflammation of your pancreas (pancreatitis). Stop using Wegovy(®) and call\nyour healthcare provider right away if you have severe pain in your stomach\narea (abdomen) that will not go away, with or without nausea or vomiting.\nSometimes you may feel the pain from your abdomen to your back\n * gallbladder problems. Wegovy(®) may cause gallbladder problems, including\ngallstones. Some gallstones may need surgery. Call your healthcare provider if\nyou have symptoms, such as pain in your upper stomach (abdomen), fever,\nyellowing of the skin or eyes (jaundice), or clay-colored stools\n * increased risk of low blood sugar (hypoglycemia), especially those who also\ntake medicines for diabetes such as insulin or sulfonylureas. This can be a\nserious side effect. Talk to your healthcare provider about how to recognize\nand treat low blood sugar and check your blood sugar before you start and\nwhile you take Wegovy(®). Signs and symptoms of low blood sugar may include\ndizziness or light-headedness, blurred vision, anxiety, irritability or mood\nchanges, sweating, slurred speech, hunger, confusion or drowsiness, shakiness,\nweakness, headache, fast heartbeat, or feeling jittery\n * dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may\ncause a loss of fluids (dehydration), which may cause kidney problems. It is\nimportant for you to drink fluids to help reduce your chance of dehydration.\nTell your healthcare provider right away if you have nausea, vomiting, or\ndiarrhea that does not go away\n * severe stomach problems. Stomach problems, sometimes severe, have been\nreported in people who use Wegovy(®.) Tell your healthcare provider if you\nhave stomach problems that are severe or will not go away\n * serious allergic reactions. Stop using Wegovy(®) and get medical help right\naway if you have any symptoms of a serious allergic reaction, including\nswelling of your face, lips, tongue, or throat; problems breathing or\nswallowing; severe rash or itching; fainting or feeling dizzy; or very rapid\nheartbeat\n * change in vision in people with type 2 diabetes. Tell your healthcare provider\nif you have changes in vision during treatment with Wegovy(®)\n * increased heart rate. Wegovy(®) can increase your heart rate while you are at\nrest. Tell your healthcare provider if you feel your heart racing or pounding\nin your chest and it lasts for several minutes\n * food or liquid getting into the lungs during surgery or other procedures that\nuse anesthesia or deep sleepiness (deep sedation). Wegovy(®) may increase the\nchance of food getting into your lungs during surgery or other procedures.\nTell all your healthcare providers that you are taking Wegovy(®) before you\nare scheduled to have surgery or other procedures\nThe most common side effects of Wegovy(®) may include: nausea, diarrhea,\nvomiting, constipation, stomach (abdomen) pain, changes in skin sensations,\nheadache, tiredness (fatigue), upset stomach, dizziness, feeling bloated,\nbelching, low blood sugar in people with type 2 diabetes, gas, stomach flu,\nheartburn, and hair loss.\n\nPlease click here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=3558436216&u=https%3A%2F%2Fwww.novo-pi.com%2Fwegovy.pdf&a=here)\n for Prescribing Information including Boxed Warning and Medication\nGuide for Wegovy(®).\n Contacts for further information\n Media:\n Liz Skrbkova (US)                                       Ambre James-Brown (Global)\n +1 609 917 0632                                         +45 3079 9289\n\nUSMediaRelations@novonordisk.com                       Globalmedia@novonordisk.com (mailto:Globalmedia@novonordisk.com)\n (mailto:USMediaRelations@novonordisk.com)\n Investors:\n Frederik Taylor Pitter (US)\n\n+1 609 613 0568\n fptr@novonordisk.com (mailto:fptr@novonordisk.com) \"\n\n Michael Novod (Global)                                  Jacob Martin Wiborg Rode (Global)\n\n+45 3075 6050\n+45 3075 5956\n nvno@novonordisk.com (mailto:nvno@novonordisk.com)      jrde@novonordisk.com (mailto:jrde@novonordisk.com)\n Sina Meyer (Global)                                     Max Ung (Global)\n\n+45 3079 6656\n+45 3077 6414\n azey@novonordisk.com (mailto:azey@novonordisk.com)      mxun@novonordisk.com (mailto:mxun@novonordisk.com)\n Christoffer Sho Togo Tullin (Global)                    Alex Bruce (Global)\n\n+45 3079 1471\n+45 3444 2613\n cftu@novonordisk.com (mailto:cftu@novonordisk.com)      axeu@novonordisk.com (mailto:axeu@novonordisk.com)\n Mads Berner Bruun (Global)\n +45 3075 2936\n mbbz@novonordisk.com (mailto:mbbz@novonordisk.com)\n\nReferences:\n\n 1. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective\nobesity care: results from the national action study. Obesity.\n2018;26(1):61–69.\n 2. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic\nrelapsing progressive disease process. A position statement of the World\nObesity Federation. Obes Rev. 2017;18(7):715–723.\n 3. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical\nendocrinologists and American College of Endocrinology comprehensive clinical\npractice guidelines for medical care of patients with obesity. Endocr Pract.\n2016;22 (Suppl 3):1–203.\n 4. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults\nwith overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI:\n10.1056/NEJMoa2500969.\n 5. Centers for Disease Control and Prevention. Risk Factors for Obesity. Last\naccessed: December 2025. Available at:\nhttps://www.cdc.gov/obesity/risk-factors/risk-factors.html\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4723065-1&h=2040965910&u=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Frisk-factors%2Frisk-factors.html&a=https%3A%2F%2Fwww.cdc.gov%2Fobesity%2Frisk-factors%2Frisk-factors.html)\n \n\n(https://mma.prnewswire.com/media/3002633/Wegovy_Pill_Combined.html)\n\n(https://mma.prnewswire.com/media/2751477/novo_Logo.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/wegovy-is-now-accessible-to-eligible-medicare-beneficiaries-living-with-obesity-through-medicare-glp-1-bridge-302815200.html\n(https://www.prnewswire.com/news-releases/wegovy-is-now-accessible-to-eligible-medicare-beneficiaries-living-with-obesity-through-medicare-glp-1-bridge-302815200.html)\n\nSOURCE Novo Nordisk\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/3002632/Wegovy_Pens_Combined.jpg\nhttps://mma.prnewswire.com/media/3002633/Wegovy_Pill_Combined.jpg\nhttps://mma.prnewswire.com/media/2751477/novo_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-07-01T11:00:04.804606423Z","server_sent_at_ms":1782903604804},"received_at":"2026-07-01T11:00:04.970Z","source_url":"https://www.prnewswire.com/news-releases/wegovy-is-now-accessible-to-eligible-medicare-beneficiaries-living-with-obesity-through-medicare-glp-1-bridge-302815200.html"},"analysis":{"id":"67027","press_release_id":"77778","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Novo Nordisk announced that Wegovy is now available to eligible Medicare beneficiaries through the Medicare GLP-1 Bridge program for a $50 monthly copay.\n\nThis new access pathway targets older adults living with obesity, leveraging Wegovy's unique FDA approval to reduce cardiovascular risk in this patient population.\n\nSince launching in January 2026, the Wegovy pill has reached 3 million prescriptions, and this program runs through the end of 2027.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Novo Nordisk secures Medicare pathway for Wegovy, expanding access for millions of seniors with obesity."},"keyFigures":{"customDimensions":{"monthly_copay":50,"prescriptions_pill":3000000}},"quotedText":"For many older Americans living with obesity, this is a moment they and their families have been waiting for.","namedEntities":{"people":[{"name":"Jamey Millar","role":"Executive Vice President, US Operations"},{"name":"Joe Nadglowski","role":"President and CEO"}],"products":["Wegovy","semaglutide"],"companies":[{"name":"Novo Nordisk","ticker":"NOVOB"},{"name":"Obesity Action Coalition (OAC)","relationship":"partner"},{"name":"Centers for Medicare & Medicaid Services (CMS)","relationship":"regulator/partner"}],"dollarAmounts":[{"amount":"$50","context":"monthly copay for eligible Medicare beneficiaries"}]},"materialImpact":{"score":3,"reasoning":"Novo Nordisk announced the inclusion of its weight-loss drug Wegovy in the Medicare GLP-1 Bridge program, significantly expanding access for eligible Medicare beneficiaries at a $50 monthly copay. While Wegovy has seen strong uptake, this specific access expansion is a positive incremental commercial development rather than a binary regulatory event or major earnings surprise."},"tickerRelevance":{"others":[],"primary":"NOVOB"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"Large-cap","eventGravity":"Commercial access expansion","sectorWeight":"Pharma/Health Care","householdBrandBoost":"Wegovy is a household name"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Novo Nordisk announced that Wegovy is now available to eligible Medicare beneficiaries through the Medicare GLP-1 Bridge program for a $50 monthly copay.\n\nThis new access pathway targets older adults living with obesity, leveraging Wegovy's unique FDA approval to reduce cardiovascular risk in this patient population.\n\nSince launching in January 2026, the Wegovy pill has reached 3 million prescriptions, and this program runs through the end of 2027.","key_figures":{"customDimensions":{"monthly_copay":50,"prescriptions_pill":3000000}},"named_entities":{"people":[{"name":"Jamey Millar","role":"Executive Vice President, US Operations"},{"name":"Joe Nadglowski","role":"President and CEO"}],"products":["Wegovy","semaglutide"],"companies":[{"name":"Novo Nordisk","ticker":"NOVOB"},{"name":"Obesity Action Coalition (OAC)","relationship":"partner"},{"name":"Centers for Medicare & Medicaid Services (CMS)","relationship":"regulator/partner"}],"dollarAmounts":[{"amount":"$50","context":"monthly copay for eligible Medicare beneficiaries"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-01T12:16:17.099Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"Large-cap","eventGravity":"Commercial access expansion","sectorWeight":"Pharma/Health Care","householdBrandBoost":"Wegovy is a household name"}},"durationMs":55598,"modelName":"george-droid-qwen-72b"}}